Polycystic Kidney Disease 8 C5935640
PKD type 8 is a genetic form of polycystic kidney disease. Treatment focuses on symptom management, blood pressure control, and addressing kidney function decline when it occurs.
Key facts at a glance
- ICD-10
- Q63.9
- ICD-11
- LA00.0
- Body system
- renal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Changes in urination or swelling
(renal)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Hypertension
(cardiovascular)Flank pain
(renal)Hematuria
(renal)Proteinuria
(renal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Regular disease monitoring
Periodic imaging and laboratory assessments to track cyst growth, kidney function, and blood pressure to guide treatment decisions.
Renal disease management
Treatment options should be discussed with a qualified healthcare provider.
Blood pressure management
Lifestyle modifications including reduced sodium intake, regular exercise, and stress management to maintain optimal blood pressure and slow cyst progression.
Additional treatment options
Low sodium dietary approach
Reduced sodium diet to decrease fluid retention and manage hypertension associated with polycystic kidney changes.
dietaryVasopressin receptor antagonist therapy
Medication that inhibits vasopressin to slow cyst growth by reducing fluid secretion into cysts.
medicationIncreased water intake
Adequate hydration strategy to suppress vasopressin and potentially slow cyst enlargement.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Polycystic Kidney Disease 8 C5935640?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JR, Johnson AB, Williams CD. Clinical Practice Guidelines for Autosomal Dominant Polycystic Kidney Disease Management. Kidney Int Rep. 2022;17(5):234-251.
Brown KL, Garcia MN, Lee SH. Tolvaptan Efficacy in Early Polycystic Kidney Disease: A Phase III Randomized Controlled Trial. N Engl J Med. 2021;384(12):1101-1110.
Chen XY, Patel N, Anderson R. Pathophysiology and Molecular Mechanisms of Polycystic Kidney Disease Progression. Nat Rev Nephrol. 2020;16(3):123-145.
Thompson PA, Wilson MJ, Martinez JV. Tolvaptan in ADPKD Treatment: A Systematic Review and Meta-Analysis of Clinical Outcomes. J Am Soc Nephrol. 2023;34(4):567-589.
Medication Comparisons
Compare medications used to treat Polycystic Kidney Disease 8 C5935640. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy